Vitiligo
☆ AI Dermatology — Free Service
In anno 2022 Stiftung Warentest ex Germania provenit, satisfactio consumptoria cum ModelDerm paulo minus fuit quam cum consultationibus telemedicinis solutis.
In anno 2022 Stiftung Warentest ex Germania provenit, satisfactio consumptoria cum ModelDerm paulo minus fuit quam cum consultationibus telemedicinis solutis.
Vitiligo digitorum difficilius est curari quam in aliis locis. Praeter quod cosmeticum deformet, vitiligo est normale, non contagiosum. In dermatologia curatio efficacissima est phototherapia seu curatio laseris (excimer) 2‑3 vice in hebdomada, pro anno saltem 1°. Si in nosocomio saepe, ob causas nummarias, ire non potes vel quia occupatus es, experiri potes machinam photographicam quae ad usum domesticum approbatur.
Vitiligo palpebrarum
Vitiligo in manibus
relevance score : -100.0%
ReferencesVitiligo communis est inordinatio cutis albae, inaequaliter distribuenda, ob amissionem melanocytorum. Recentes investigationes indicant morbum esse autoimmune. Cum saepe medicamentum ad prophylaxis adhibetur, tamen potest penitus afficere mentem, bonum statum mentis ac vitam cotidianam. Anno 2011 periti, qui segmentum vitiligo a reliquis distinguunt, seorsim nominaverunt.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Patientibus vitiligo plures optiones curandi sunt, inter quas glucocorticoides systemici, phototherapia et immunosuppressiva systemica. Vitiligo stabilis remedium potest inveniri per corticosteroides topicos, inhibitores calcineurini, phototherapiam, atque rationes transplantationis. Recentes progressiones in intellegentia processus vitiliginis ad evolutionem novarum therapiae iaculis duxerunt. In praesenti, inhibitores JAK promissi sunt, bonam tolerabilitatem et effectus favorabiles praebentes, quamquam periculum infectionum latenter activarum et effectus systemici cum aliis immunosuppressivis agentibus manet. Investigationes permanentes intendunt cognoscere cytokinos clavos implicatos in progressione vitiliginis (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF). Haec cytokina in exemplis animalibus et quibusdam patientibus promittunt. Accedunt etiam studia de therapia ad miRNA fundata et de therapia adoptiva Treg cellorum.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Remedium vitiligo notum non est. Cura cum cutis levissima, protectio solaris (sunscreen) et rutrum sunt omnia quae typice commendantur. Aliæ optiones curationis includere possunt steroides topicos vel phototherapy.
○ Curatio
#Phototherapy
#Excimer laser
#Tacrolimus ointment